m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00633
 [1], [2], [3]
m6A modification MIR22 MIR22 FTO Demethylation : m6A sites Indirect Enhancement RNA modification NLRP3 NLRP3 ADARB2 Methylation : modification sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target hsa-mir-22
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Double-stranded RNA-specific editase B2 (ADARB2) WRITER View Details
Regulated Target NACHT, LRR and PYD domains-containing protein 3 (NLRP3) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary FTO interacts with hsa-mir-22, increasing its m6A level and promoting its physical interaction with NACHT, LRR and PYD domains-containing protein 3 (NLRP3), which was regulated by ADARB2-mediated A-to-I modification.
In-vitro Model
 HEK293 Normal Homo sapiens CVCL_0045
HEK293 Normal Homo sapiens CVCL_0045
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Dapansutrile Phase 2 [4]
Synonyms
54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 12714644
TTD: D0TH5H
 Compound Name BMS-986299 Phase 1 [5]
MOA Agonist
External Link
TTD: D75LNO
 Compound Name Selnoflast Phase 1 [6]
Synonyms
1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 137402358
TTD: D7KRB9
 Compound Name MCC950 Investigative [7]
Synonyms
210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 9910393
TTD: D09FGL
References
Ref 1 ADAR3 alleviated inflammation and pyroptosis of neuropathic pain by targeting NLRP3 in chronic constriction injury mice. Gene. 2021 Dec 30;805:145909. doi: 10.1016/j.gene.2021.145909. Epub 2021 Aug 19.
Ref 2 N6-adenosine methylation in MiRNAs. PLoS One. 2015 Feb 27;10(2):e0118438. doi: 10.1371/journal.pone.0118438. eCollection 2015.
Ref 3 LncRNA-HOTAIR promotes endothelial cell pyroptosis by regulating the miR-22/NLRP3 axis in hyperuricaemia. J Cell Mol Med. 2021 Sep;25(17):8504-8521. doi: 10.1111/jcmm.16812. Epub 2021 Jul 22.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 National Cancer Institute Drug Dictionary (drug name BMS-986299).
Ref 6 Clinical pipeline report, company report or official report of Roche
Ref 7 A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015 Mar;21(3):248-55.